CSPC Pharma Sets March Board Meeting to Approve 2025 Results and Consider Dividend

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.

CSPC Pharmaceutical Group has scheduled a board meeting for 25 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. At the same meeting, the board will also consider the declaration of a final dividend, a decision that could influence shareholder returns and signal management’s confidence in the company’s financial performance.

The timing of the meeting aligns with the group’s regular financial reporting cycle and provides investors with a clear expectation for the release of full-year figures. The announcement also confirms the current composition of the board, underscoring the mix of executive and independent non-executive directors overseeing the company’s governance and strategic direction.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group operates through multiple subsidiaries and focuses on the development, production, and sale of pharmaceutical products, serving both domestic and international healthcare markets.

Average Trading Volume: 120,943,263

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$99.5B

For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.